Arixtra and Pramine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Arixtra and Pramine. Common interactions include drug administration error among females and activated partial thromboplastin time prolonged among males.

The phase IV clinical study analyzes what interactions people who take Arixtra and Pramine have. It is created by eHealthMe based on reports of 6 people who take Arixtra and Pramine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 05, 2022

6 people who take Arixtra and Pramine together, and have interactions are studied.


What is Arixtra?

Arixtra has active ingredients of fondaparinux sodium. It is often used in deep venous thrombosis. eHealthMe is studying from 9,518 Arixtra users for its effectiveness, alternative drugs and more.

What is Pramine?

Pramine has active ingredients of imipramine hydrochloride. eHealthMe is studying from 7,069 Pramine users for its effectiveness, alternative drugs and more.

Number of Arixtra and Pramine reports submitted per year:

Arixtra and Pramine drug interactions.

Common Arixtra and Pramine drug interactions by gender *:

female:

  1. Drug administration error
  2. Haemoglobin decreased
  3. Post procedural haematoma
  4. Red blood cell count decreased
  5. Weight increased
  6. White blood cell count increased

male:

  1. Activated partial thromboplastin time prolonged
  2. Renal failure acute
  3. Pyrexia
  4. Spinal compression fracture
  5. Renal tubular necrosis
  6. Abdominal discomfort
  7. Fatigue
  8. Jugular vein thrombosis
  9. Local swelling
  10. Malaise

Common Arixtra and Pramine drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Drug administration error
  2. Weight increased

50-59:

n/a

60+:

  1. Activated partial thromboplastin time prolonged
  2. Renal failure acute
  3. Post procedural haematoma
  4. Postoperative hypotension
  5. Pyrexia
  6. Red blood cell count decreased
  7. Spinal compression fracture
  8. White blood cell count increased
  9. Renal tubular necrosis
  10. Abdominal discomfort

* Approximation only. Some reports may have incomplete information.

Do you take Arixtra and Pramine?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Arixtra and Pramine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Arixtra interactions:

Browse all interactions between Arixtra and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Pramine interactions:

Browse all interactions between Pramine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on fondaparinux sodium and imipramine hydrochloride (the active ingredients of Arixtra and Pramine, respectively), and Arixtra and Pramine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Arixtra and Pramine.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: